COVAX - Time to reconsider the strategy and its target - Archive ouverte HAL Access content directly
Journal Articles Health Policy OPEN Year : 2023

COVAX - Time to reconsider the strategy and its target


COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion US dollars already committed. While some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. First, mass COVID-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. Second, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. We conclude that the COVAX initiative warrants urgent review.

Dates and versions

hal-04149586 , version 1 (03-07-2023)



David Bell, Garrett W Brown, Wellington A Oyibo, Samiratou Ouédraogo, Blagovesta Tacheva, et al.. COVAX - Time to reconsider the strategy and its target. Health Policy OPEN, 2023, 4, pp.100096. ⟨10.1016/j.hpopen.2023.100096⟩. ⟨hal-04149586⟩
23 View
0 Download



Gmail Facebook Twitter LinkedIn More